Disorders of mitochondrial fatty acid oxidation and related metabolic pathways

Inborn Metabolic Diseases: Diagnosis and Treatment

Volumn , Issue , 2012, Pages 201-216

  Morris, Andrew A M ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906562474     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-15720-2_13     Document Type: Chapter

References (78)

1. Bonnet D, Martin D, Pascale De L et al. (1999) Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 100:2248-2253
2. Jia Z, Pei Z, Maiguel D et al. (2007) The fatty acid transport protein (FATP) family: very long chain acyl-CoA synthetases or solute carriers? J Mol Neurosci 33:25-31
3. Odaib AA, Shneider BL, Bennett MJ et al. (1998) A defect in the transport of long-chain fatty acids associated with acute liver failure. N Engl J Med 339:1752-1757
4. Stanley CA, DeLeeuw S, Coates PM et al. (1991) Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 30:709-716
5. Vijay S, Patterson A, Olpin S et al. (2006) Carnitine transporter defect: diagnosis in asymptomatic adult women following analysis of acylcarnitines in their newborn infants. J Inherit Metab Dis 29:627-630
6. Olpin SE, Allen J, Bonham JR et al. (2001) Features of carnitine palmitoyltransferase type I deficiency. J Inherit Metab Dis 24:35-42
7. Falik-Borenstein ZC, Jordan SC, Saudubray JM et al. (1992) Brief report: renal tubular acidosis in carnitine palmitoyltransferase type 1 deficiency. N Engl J Med 327:24-27
8. Greenberg CR, Dilling LA, Thompson GR et al. (2009) The paradox of the carnitine palmitoyltransferase type Ia P479L variant in Canadian Aboriginal populations. Mol Genet Metab 96:201-207
9. Stanley CA, Hale DE, Berry GT et al. (1992) Brief report: a deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 327:19-23
10. Pande SV, Brivet M, Slama A et al. (1993) Carnitine-acylcarnitine translocase deficiency with severe hypoglycemia and auriculo ventricular block. Translocase assay in permeabilized fibroblasts. J Clin Invest 91:1247-1252
11. Morris AA, Olpin SE, Brivet M et al. (1998) A patient with carnitine- acylcarnitine translocase deficiency with a mild phenotype. J Pediatr 132:514-516
12. DiMauro S, DiMauro PM (1973) Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science 182:929-931
13. North KN, Hoppel CL, De Girolami U et al. (1995) Lethal neonatal deficiency of carnitine palmitoyltransferase II associated with dysgenesis of the brain and kidneys. J Pediatr 127:414-420
14. Demaugre F, Bonnefont JP, Colonna M et al. (1991) Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest 87:859-864
15. Andresen BS, Olpin S, Poorthuis BJ et al. (1999) Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 64:479-494
16. Ogilvie I, Pourfarzam M, Jackson S et al. (1994) Very long-chain acyl coenzyme A dehydrogenase deficiency presenting with exercise-induced myoglobinuria. Neurology 44:467-473
17. Brown-Harrison MC, Nada MA, Sprecher H et al. (1996) Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem Mol Med 58:59-65
18. Spiekerkoetter U, Haussmann U, Mueller M et al. (2010) Tandem mass spectrometry screening for very long-chain acyl-CoA dehydrogenase deficiency: the value of second-tier enzyme testing. J Pediatr 157:668-673
19. Den Boer ME, Wanders RJ, Morris AA et al. (2002) Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics 109:99-104
20. Tyni T, Rapola J, Palotie A et al. (1997) Hypoparathyroidism in a patient with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency caused by the G1528C mutation. J Pediatr 131:766-768
21. Tyni T, Kivela T, Lappi M et al. (1998) Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy. Ophthalmology 105:810-824
22. Spiekerkoetter U, Khuchua Z, Yue Z et al. (2004) General mitochondrial trifunctional protein (TFP) deficiency as a result of either alpha- or beta-subunit mutations exhibits similar phenotypes because mutations in either subunit alter TFP complex expression and subunit turnover. Pediatr Res 55:190-196
23. Schaefer J, Jackson S, Dick DJ et al. (1996) Trifunctional enzyme deficiency: adult presentation of a usually fatal beta-oxidation defect. Ann Neurol 40:597-602
24. Wilcken B, Leung KC, Hammond J et al. (1993) Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet 341:407-408
25. Pourfarzam M, Morris A, Appleton M et al. (2001) Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet 358:1063-1064
26. Andresen BS, Dobrowolski SF, O’Reilly L et al. (2001) Mediumchain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 68:1408-1418
27. Wilcken B, Haas M, Joy P et al. (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369:37-42
28. Wilcken B, Carpenter KH, Hammond J (1993) Neonatal symptoms in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 69:292-294
29. Mayell SJ, Edwards L, Reynolds FE et al. (2007) Late presentation of medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 30:104
30. Kamijo T, Indo Y, Souri M et al. (1997) Medium chain 3-ketoacyl- coenzyme A thiolase deficiency: a new disorder of mitochondrial fatty acid beta-oxidation. Pediatr Res 42:569-576
31. Maldegem v BT, Duran M, Wanders RJ et al. (2006) Clinical, biochemical, and genetic heterogeneity in short-chain acylcoenzyme A dehydrogenase deficiency. JAMA 296:943-952
32. Clayton PT, Eaton S, Aynsley-Green A et al. (2001) Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. J Clin Invest 108:457-465
33. Li C, Chen P, Palladino A et al. (2010) Mechanism of hyperinsulinism in short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency involves activation of glutamate dehydrogenase. J Biol Chem 285:31806-31818
34. Bennett MJ, Russell LK, Tokunaga C et al. (2006) Reye-like syndrome resulting from novel missense mutations in mitochondrial medium- and short-chain l-3-hydroxy-acyl-CoA dehydrogenase. Mol Genet Metab 89:74-79
35. Nouws J, Nijtmans L, Houten SM et al. (2010) Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. Cell Metab 12:283-294
36. Haack TB, Danhauser K, Haberberger B et al. (2010) Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet 42:1131-1134 [36b] Sufrie KRS, Karunanidhi AK, Mohsen WM et al. (2011) Long Chain Acyl-CoA dehydrogenase deficiency: a new inborn of metabolism manifesting as congenital surfactant deficiency. S. Inherit Metab Dis 34 (Suppl 3) S149 (abstract)
37. Roe CR, Millington DS, Norwood DL et al. (1990) 2,4-Dienoylcoenzyme A reductase deficiency: a possible new disorder of fatty acid oxidation. J Clin Invest 85:1703-1707
38. Colevas AD, Edwards JL, Hruban RH et al. (1988) Glutaric acidemia type II.Comparison of pathologic features in two infants. Arch Pathol Lab Med 112:1133-1139
39. Olsen RK, Olpin SE, Andresen BS et al. (2007) ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130:2045-2054
40. Hove v JL, Grunewald S, Jaeken J et al. (2003) d, l-3-Hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet 361:1433-1435
41. Bosch AM, Abeling NG, IJlst L et al. (2011) Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. J Inherit Metab Dis 34:165-171
42. Ho G, Yonezawa A, Masuda S et al. (2011) Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Hum Mutat 32:E1976-1984
43. Herrema H, Derks TG, Dijk v TH et al. (2008) Disturbed hepatic carbohydrate management during high metabolic demand in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice. Hepatology 47:1894-1904
44. Fletcher JM, Pitt JJ (2001) Fasting medium chain acyl-coenzyme A dehydrogenase--deficient children can make ketones. Metabolism 50:161-165
45. Ventura FV, Ruiter JP, L IJ et al. (1998) Lactic acidosis in long-chain fatty acid beta-oxidation disorders. J Inherit Metab Dis 21:645-654
46. Corr PB, Creer MH, Yamada KA et al. (1989) Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 83:927-936
47. Gillingham MB, Weleber RG, Neuringer M et al. (2005) Effect of optimal dietary therapy upon visual function in children with long-chain 3-hydroxyacyl CoA dehydrogenase and trifunctional protein deficiency. Mol Genet Metab 86:124-133
48. Vockley J, Rinaldo P, Bennett MJ et al. (2000) Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol Genet Metab 71:10-18
49. Schuler AM, Gower BA, Matern D et al. (2005) Synergistic heterozygosity in mice with inherited enzyme deficiencies of mitochondrial fatty acid beta-oxidation. Mol Genet Metab 85:7-11
50. Taroni F, Verderio E, Dworzak F et al. (1993) Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat Genet 4:314-320
51. IJlst L, Ruiter JP, Hoovers JM et al. (1996) Common missense mutation G1528C in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Characterization and expression of the mutant protein, mutation analysis on genomic DNA and chromosomal localization of the mitochondrial trifunctional protein alpha subunit gene. J Clin Invest 98:1028-1033
52. Gempel K, Kiechl S, Hofmann S et al. (2002) Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis 25:17-27
53. Primassin S, Spiekerkoetter U (2010) ESI-MS/MS measurement of free carnitine and its precursor gamma-butyrobetaine in plasma and dried blood spots from patients with organic acidurias and fatty acid oxidation disorders. Mol Genet Metab 101:141-145
54. Wilcken B, Wiley V, Sim KG et al. (2001) Carnitine transporter defect diagnosed by newborn screening with electrospray tandem mass spectrometry. J Pediatr 138:581-584
55. Stanley CA, Berry GT, Bennett MJ et al. (1993) Renal handling of carnitine in secondary carnitine deficiency disorders. Pediatr Res 34:89-97
56. Stanley CA, Sunaryo F, Hale DE et al. (1992) Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency. J Inherit Metab Dis 15:785-789
57. Costa CG, Guerand WS, Struys EA et al. (2000) Quantitative analysis of urinary acylglycines for the diagnosis of beta-oxidation defects using GC-NCI-MS. J Pharm Biomed Anal 21:1215-1224
58. Wanders RJ, Ruiter JP, Ijlst L et al. (2010) The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results. J Inherit Metab Dis 33:479-494
59. Ventura FV, Costa CG, Struys EA et al. (1999) Quantitative acylcarnitine profiling in fibroblasts using [U-13C] palmitic acid: an improved tool for the diagnosis of fatty acid oxidation defects. Clin Chim Acta 281:1-17
60. Sim KG, Carpenter K, Hammond J et al. (2002) Acylcarnitine profiles in fibroblasts from patients with respiratory chain defects can resemble those from patients with mitochondrial fatty acid beta-oxidation disorders. Metabolism 51:366-371
61. Olpin SE, Manning NJ, Pollitt RJ et al. (1997) Improved detection of long-chain fatty acid oxidation defects in intact cells using [9,10-3H]oleic acid. J Inherit Metab Dis 20:415-419
62. Morris AA, Thekekara A, Wilks Z et al. (1996) Evaluation of fasts for investigating hypoglycaemia or suspected metabolic disease. Arch Dis Child 75:115-119
63. Bonnefont JP, Specola NB, Vassault A et al. (1990) The fasting test in paediatrics: application to the diagnosis of pathological hypoand hyperketotic states. Eur J Pediatr 150:80-85
64. Dixon MA, Leonard JV (1992) Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Child 67:1387-1391
65. Spiekerkoetter U (2007) Effects of a fat load and exercise on asymptomatic VLCAD deficiency. J Inherit Metab Dis 30:405
66. Spiekerkoetter U, Lindner M, Santer R et al. (2009) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 32:498-505
67. Arnold GL, Hove v J, Freedenberg D et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl- CoA dehydrogenase deficiency. Mol Genet Metab 96:85-90
68. Roe CR, Sweetman L, Roe DS et al. (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110:259-269
69. Roe CR, Yang BZ, Brunengraber H et al. (2008) Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 71:260-264
70. Lieu YK, Hsu BY, Price WA et al. (1997) Carnitine effects on coenzyme A profiles in rat liver with hypoglycin inhibition of multiple dehydrogenases. Am J Physiol 272:E359-366
71. Gobin-Limballe S, Djouadi F, Aubey F et al. (2007) Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am J Hum Genet 81:1133-1143
72. Bonnefont JP, Bastin J, Behin A et al. (2009) Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 360:838-840
73. Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 33:501-506
74. Mayatepek E, Flock B (1998) Leukotriene C4-synthesis deficiency: a new inborn error of metabolism linked to a fatal developmental syndrome. Lancet 352:1514-1517
75. Willemsen MA, L IJ, Steijlen PM et al. (2001) Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjogren-Larsson syndrome. Brain 124:1426-1437
76. Willemsen MA, Rotteveel JJ, de Jong JG et al. (2001) Defective metabolism of leukotriene B4 in the Sjogren-Larsson syndrome. J Neurol Sci 183:61-67
77. Sanders RJ, Ofman R, Dekker C et al. (2009) Enzymatic diagnosis of Sjogren-Larsson syndrome using electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:451-455
78. Willemsen MA, Lutt MA, Steijlen PM et al. (2001) Clinical and biochemical effects of zileuton in patients with the Sjogren-Larsson syndrome. Eur J Pediatr 160:711-717